eFFECTOR Therapeutics Return on Equity

eFFECTOR Therapeutics (EFTR) currently reports a ROE of 2.37%. That is below the Healthcare sector average of 21.67%. Use the charts on this page to explore eFFECTOR Therapeutics's ROE history and peer comparisons.

eFFECTOR Therapeutics's ROE of 2.37% is lower than the Healthcare sector average of 21.67%. That is roughly 89.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but eFFECTOR Therapeutics's current 2.37% should be judged against Healthcare norms (sector average: 21.67%) and against EFTR's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 2.37%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for eFFECTOR Therapeutics, and consider following EFTR for alerts when major investors trade the stock.

eFFECTOR Therapeutics is classified in the Healthcare sector. On ROE, it currently shows 2.37% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EFTR with unrelated industries.